Multidisciplinary Tumor Board Recommendations for Oligometastatic Malignancies: A Prospective Single-Center Analysis.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Brain
/ surgery
Brain Neoplasms
/ secondary
Chemotherapy, Adjuvant
/ methods
Clinical Decision-Making
Female
Humans
Interdisciplinary Communication
Liver
/ surgery
Liver Neoplasms
/ secondary
Lung
/ surgery
Lung Neoplasms
/ secondary
Male
Middle Aged
Patient Care Team
/ standards
Patient Selection
Practice Guidelines as Topic
Prospective Studies
Treatment Outcome
Watchful Waiting
Interventional therapy
Multidisciplinary tumor board
Oligometastases
Radiation therapy
Surgery
Journal
Oncology research and treatment
ISSN: 2296-5262
Titre abrégé: Oncol Res Treat
Pays: Switzerland
ID NLM: 101627692
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
09
2018
accepted:
15
11
2018
pubmed:
1
3
2019
medline:
20
8
2019
entrez:
1
3
2019
Statut:
ppublish
Résumé
The treatment of oligometastatic disease is challenging and few data exist to guide treatment decisions. The objective of this study was to improve the data on the prevalence and treatment of patients with oligometastatic disease. We conducted a prospective single-center analysis that included all consecutive patients discussed in multidisciplinary tumor boards (MDT) between February and July 2017. Patients with oligometastatic disease were identified and treatment strategies were evaluated. 1,673 patients were included in this study, 609 (36.4%) presented with metastatic disease, 151 (9%) had oligometastatic disease. Common metastatic sites were brain, liver, and lung. Lung cancer patients were the largest cohort (20.5%) among all patients with oligometastatic disease compared with other tumor entities. The majority of oligometastatic patients (68.9%) received local treatment with or without additional chemotherapy, 17.9% were recommended systemic therapy alone. MDT recommended watchful waiting for 4.6% of the patients. Patients with oligometastatic disease represent a considerable proportion of all patients in MDT. In this study, 68.9% of patients with oligometastatic disease received regional treatment. This shows a possible treatment shift from palliative to potentially curative intent. These data may be used to design prospective clinical trials to optimize the treatment of oligometastatic disease.
Sections du résumé
BACKGROUND
BACKGROUND
The treatment of oligometastatic disease is challenging and few data exist to guide treatment decisions. The objective of this study was to improve the data on the prevalence and treatment of patients with oligometastatic disease.
METHODS
METHODS
We conducted a prospective single-center analysis that included all consecutive patients discussed in multidisciplinary tumor boards (MDT) between February and July 2017. Patients with oligometastatic disease were identified and treatment strategies were evaluated.
RESULTS
RESULTS
1,673 patients were included in this study, 609 (36.4%) presented with metastatic disease, 151 (9%) had oligometastatic disease. Common metastatic sites were brain, liver, and lung. Lung cancer patients were the largest cohort (20.5%) among all patients with oligometastatic disease compared with other tumor entities. The majority of oligometastatic patients (68.9%) received local treatment with or without additional chemotherapy, 17.9% were recommended systemic therapy alone. MDT recommended watchful waiting for 4.6% of the patients.
CONCLUSION
CONCLUSIONS
Patients with oligometastatic disease represent a considerable proportion of all patients in MDT. In this study, 68.9% of patients with oligometastatic disease received regional treatment. This shows a possible treatment shift from palliative to potentially curative intent. These data may be used to design prospective clinical trials to optimize the treatment of oligometastatic disease.
Identifiants
pubmed: 30814474
pii: 000495474
doi: 10.1159/000495474
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Pagination
87-94Informations de copyright
© 2019 S. Karger AG, Basel.